156 Address for Correspondence: Esra Savku MD, Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey Phone: +90 312 595 62 60 E-mail: [email protected] Received: 11.06.2014 Accepted: 02.11.2014 Objectives: To discuss our follow-up and treatment results in thyroid-associated ophthalmopathy (TAO). Ma te ri als and Met hods: The records of 168 TAO cases who were followe...

The literature analysis confirms the interrelationship of thyroid gland pathology and glaucoma. Patients with diffusetoxic goiter (DTG) endemic have an especially high risk developing glaucoma, while those autoimmune thyroiditis face a moderate risk. prevalence primary open angle glaucoma (POAG) in patients over 40 endocrine ophthalmopathy is reliably associated male gender duration disease lon...

AIM To assess levels of soluble Fas (sFas) in the sera of patients with Graves' ophthalmopathy. METHODS The subjects in this study were 43 patients with Graves' ophthalmopathy and 11 normal subjects. Serum levels of sFas were determined by sandwich enzyme linked immunosorbent assay. In addition, serum levels of thyroid stimulating antibody (TSAB) were also measured in all the patients. RESU...

Thyroid eye disease can lead to impaired social and physical functioning. A patient’s quality of life is greatly affected, and physicians often feel powerless to control this progressive disease. Patients with thyroid eye disease (also known as Graves ophthalmopathy [GO]) frequently experience cosmetic disfigurement and functional disability. Pain, proptosis, ocular injection, swelling of the e...

OBJECTIVE Ipilimumab is a fully human MAB against cytotoxic T-lymphocyte antigen 4 (CTLA4). CTLA4 negatively regulates immune cell activation. In patients with metastatic melanoma, ipilimumab increases survival time and induces complete remission in some patients. However, immune-related adverse events including endocrinopathies have been reported. Bevacizumab, an angiogenesis inhibitor, has be...

Abstract Introduction The impact of thyroidectomy for Graves’ disease (GD) on ophthalmopathy (GO) is not well understood. It generally accepted that does exacerbate or precipitate GO in the majority. aim this study was to evaluate whether prophylactic glucocorticoid use following total GD prevents early post-operative reactivation GO. Methods A retrospective cohort covering 5 years, studying pa...

BACKGROUND The development of Graves' disease (GD) after subacute thyroiditis (SAT) is very rare and only a limited number of cases have been reported. OBJECTIVES Here, we report a patient with SAT followed by hypothyroidism and later GD, with ophthalmopathy, occurring 11 years after SAT. CONCLUSION This case illustrates the appearance of thyroid-stimulating hormone (TSH) receptor antibodie...

Graves’ disease was first recognized in the 19th century as a syndrome comprising an enlarged and overactive thyroid gland, an accelerated heart rate, and ocular abnormalities (Fig. 1). Critical for our current understanding of this disease was the discovery of its autoimmune basis, which results from complex interactions between genetic and environmental factors.1,2 Graves’ disease has adverse...